Eli Lilly is building a $5 billion manufacturing facility in Richmond, Va. It is the company’s first fully integrated facility for active pharmaceutical ingredients.
The site is also intended to support the drugmaker’s bioconjugate platform and monoclonal antibody portfolio, including antibody drug conjugates for cancer, autoimmune diseases and other conditions, according to an Sept. 16 news release from Eli Lilly.
The project is a part of Eli Lilly’s effort to expand domestic pharmaceutical manufacturing, with this being the first of four sites the company plans to announce this year. The new integrated facility is expected to be up and running within five years.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
